As it is conceivable that some cancers are primarily driven by the MET mutations [31], to date, METamp and METex14, have shown their actionability in NSCLC, such as prognosis, and expanding the therapeutic opportunities for patients without EGFR and ALK as usual alterations [32]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.